Inhibikase Therapeutics, Inc.(IKT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $3.1M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IKT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Inhibikase Therapeutics, Inc. (IKT), a Healthcare sector company. IKT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $3.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Inhibikase Therapeutics, Inc. reports net income of $-19.6M, free cash flow of $-12.4M. Top institutional holders of IKT by reported 13-F value include Sands Capital Ventures, Soleus Capital Management, L.P., Trails Edge Capital Partners, based on the most recent SEC filings. IKT trades on the Nasdaq exchange and files with the SEC under CIK 1750149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibikase Therapeutics, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-19.6M
Free Cash Flow
Q2 2026
$-12.4M
ROIC
Q2 2026
-54.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-75.4% YoYOperating Income
-81.8% YoYEPS (Diluted)
+57.8% YoYTotal Assets
+83.8% YoYTotal Debt
-100.0% YoYOp. Cash Flow
-45.1% YoYFree Cash Flow
-45.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 -100.0% | $260.5K +111.0% | $123.4K -96.0% | $3.1M +343.9% | $698.5K |
| Net Income | $-48.3M -75.4% | $-27.5M -44.6% | $-19.0M -5.4% | $-18.1M -22.1% | $-14.8M -419.2% | $-2.8M |
| Operating Income | $-52.0M -81.8% | $-28.6M -42.3% | $-20.1M -10.8% | $-18.1M -22.8% | $-14.8M -423.9% | $-2.8M |
| EPS (Diluted) | $-0.49 +57.8% | $-1.16 +63.3% | $-3.16 +26.2% | $-4.28 -428.4% | $-0.81 | — |
| Total Assets | $181.2M +83.8% | $98.6M +579.7% | $14.5M -41.8% | $24.9M -41.3% | $42.5M +187.3% | $14.8M |
| Total Debt | $0.00 -100.0% | $110.5K -79.2% | $531.9K +264.7% | $145.8K -41.4% | $248.9K | — |
| Operating Cash Flow | $-27.8M -45.1% | $-19.1M -5.9% | $-18.1M -4.2% | $-17.4M -21.4% | $-14.3M -1165.9% | $-1.1M |
| Free Cash Flow | $-27.8M -45.2% | $-19.1M -5.8% | $-18.1M -2.9% | $-17.6M -23.1% | $-14.3M | — |
Get alerted when IKT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Inhibikase Therapeutics, Inc. including:
Top Institutional Holders of IKT
Sands Capital Ventures, LLC
$26.4M13,018,965 shSoleus Capital Management, L.P.
$22.1M10,875,000 shTrails Edge Capital Partners, LP
$18.4M9,051,318 shFairmount Funds Management LLC
$17.5M8,625,000 shBlackRock, Inc.
$15.8M7,768,057 shADAR1 Capital Management, LLC
$15.0M7,387,205 shBlackstone Inc.
$12.1M5,938,276 shSiren, L.L.C.
$11.9M5,850,000 shCommodore Capital LP
$11.0M5,397,488 shVANGUARD CAPITAL MANAGEMENT LLC
$10.0M4,935,354 sh
| Fund | Value | Shares |
|---|---|---|
| Sands Capital Ventures, LLC | $26.4M | 13,018,965 |
| Soleus Capital Management, L.P. | $22.1M | 10,875,000 |
| Trails Edge Capital Partners, LP | $18.4M | 9,051,318 |
| Fairmount Funds Management LLC | $17.5M | 8,625,000 |
| BlackRock, Inc. | $15.8M | 7,768,057 |
| ADAR1 Capital Management, LLC | $15.0M | 7,387,205 |
| Blackstone Inc. | $12.1M | 5,938,276 |
| Siren, L.L.C. | $11.9M | 5,850,000 |
| Commodore Capital LP | $11.0M | 5,397,488 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.0M | 4,935,354 |
More Healthcare Companies
View all Healthcare →Put IKT on your watchlist
Track score changes the day Inhibikase Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IKT a good stock to buy?
13F Pro's AI-powered analysis of Inhibikase Therapeutics, Inc. (IKT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IKT are available on the IKT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IKT is classified as a small company.
Which hedge funds own IKT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IKT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inhibikase Therapeutics, Inc.'s investment landscape.